These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 26124346)

  • 1. Evaluation of Bone Metastasis Using Serial Measurements of Serum N-Telopeptides of Type I Collagen in Patients with Lung Cancer: A Prospective Study.
    Tamiya M; Tokunaga S; Okada H; Suzuki H; Sasada S; Okamoto N; Morishita N; Shiroyama T; Otsuka T; Miyamoto N; Taira K; Daga H; Takeda K; Hirashima T
    Anticancer Res; 2015 Jul; 35(7):3987-93. PubMed ID: 26124346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective study of urinary and serum cross-linked N-telopeptide of type I collagen (NTx) for diagnosis of bone metastasis in patients with lung cancer.
    Tamiya M; Tokunaga S; Okada H; Suzuki H; Kobayashi M; Sasada S; Okamoto N; Morishita N; Matsuura Y; Miyamoto N; Hattori M; Taira K; Daga H; Takeda K; Hirashima T
    Clin Lung Cancer; 2013 Jul; 14(4):364-9. PubMed ID: 23276824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum N-telopeptide of type I collagen and bone alkaline phosphatase and their relationship in patients with non-small cell lung carcinoma and bone metastases. Preliminary results.
    Lumachi F; Marino F; Fanti G; Chiara GB; Basso SM
    Anticancer Res; 2011 Nov; 31(11):3879-81. PubMed ID: 22110213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of the serum crosslinked N-telopeptide of type I collagen as a prognostic marker for non-small-cell lung cancer.
    Tamiya M; Kobayashi M; Morimura O; Yasue T; Nakasuji T; Satomu M; Kohei O; Takayuki S; Morishita N; Suzuki H; Sasada S; Okamoto N; Hirashima T; Kawase I
    Clin Lung Cancer; 2013 Jan; 14(1):50-4. PubMed ID: 22609050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid.
    Pectasides D; Nikolaou M; Farmakis D; Kanakis I; Gaglia A; Kountourakis P; Karamanos NK; Economopoulos T; Raptis SA
    Anticancer Res; 2005; 25(2B):1457-63. PubMed ID: 15865105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis.
    Koizumi M; Takahashi S; Ogata E
    Anticancer Res; 2003; 23(5b):4095-9. PubMed ID: 14666607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of urine type I collagen-cross-linked N telopeptide levels with bone scintigraphic results in prostate cancer patients.
    Fukumitsu N; Uchiyama M; Mori Y; Yanada S; Hatano T; Igarashi H; Kishimoto K; Nakada J; Yoshihiro A; Harada J
    Metabolism; 2002 Jul; 51(7):814-8. PubMed ID: 12077723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of a short-term treatment with alendronate on bone density and bone markers in patients with central diabetes insipidus.
    Pivonello R; Faggiano A; Di Somma C; Klain M; Filippella M; Salvatore M; Lombardi G; Colao A
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2349-52. PubMed ID: 10404801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-Telopeptide of Type I Collagen Long-Term Dynamics in Breast Cancer Patients With Bone Metastases: Clinical Outcomes and Influence of Extraskeletal Metastases.
    Ferreira AR; Alho I; Shan N; Matias M; Faria M; Casimiro S; Leitzel K; Ali S; Lipton A; Costa L
    Oncologist; 2016 Dec; 21(12):1418-1426. PubMed ID: 27534575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum C-telopeptide levels predict the incidence of skeletal-related events in cancer patients with secondary bone metastases.
    López-Carrizosa MC; Samper-Ots PM; Pérez AR
    Clin Transl Oncol; 2010 Aug; 12(8):568-73. PubMed ID: 20709654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of gonadal steroid suppression on skeletal sensitivity to parathyroid hormone in men.
    Leder BZ; Smith MR; Fallon MA; Lee ML; Finkelstein JS
    J Clin Endocrinol Metab; 2001 Feb; 86(2):511-6. PubMed ID: 11158001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness of the serum cross-linked N-telopeptide of type I collagen as a marker of bone metastasis from lung cancer.
    Tamiya M; Suzuki H; Kobayashi M; Sasada S; Okamoto N; Morishita N; Yasue T; Matsuura Y; Hirashima T; Kawase I
    Med Oncol; 2012 Mar; 29(1):215-8. PubMed ID: 21258879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice.
    Lu S; Zhang J; Zhou Z; Liao ML; He WZ; Zhou XY; Li ZM; Xiang JQ; Wang JJ; Chen HQ
    Oncol Rep; 2008 Sep; 20(3):581-7. PubMed ID: 18695909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RANK/RANK-L/OPG in patients with bone metastases treated with anticancer agents and zoledronic acid: a prospective study.
    Mercatali L; Ricci M; Scarpi E; Serra P; Fabbri F; Ricci R; Liverani C; Zanoni M; Zoli W; Maltoni R; Gunelli E; Amadori D; Ibrahim T
    Int J Mol Sci; 2013 May; 14(6):10683-93. PubMed ID: 23702841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic Acid for detection of bone metastases progression.
    Lein M; Wirth M; Miller K; Eickenberg HU; Weissbach L; Schmidt K; Haus U; Stephan C; Meissner S; Loening SA; Jung K
    Eur Urol; 2007 Nov; 52(5):1381-7. PubMed ID: 17321667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid.
    Coleman RE; Major P; Lipton A; Brown JE; Lee KA; Smith M; Saad F; Zheng M; Hei YJ; Seaman J; Cook R
    J Clin Oncol; 2005 Aug; 23(22):4925-35. PubMed ID: 15983391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated N-telopeptide as a potential diagnostic marker for bone metastasis in lung cancer: A meta-analysis.
    Liu B; Zhao Y; Yuan J; Zeng L; Sun R; Meng X; Yang S
    PLoS One; 2017; 12(11):e0187860. PubMed ID: 29182642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade.
    Kamiya N; Suzuki H; Endo T; Takano M; Yano M; Naoi M; Nishimi D; Kawamura K; Imamoto T; Ichikawa T
    Int J Urol; 2012 Feb; 19(2):169-73. PubMed ID: 22126137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum N-telopeptide and bone-specific alkaline phosphatase levels in patients with osteonecrosis of the jaw receiving bisphosphonates for bone metastases.
    Morris PG; Fazio M; Farooki A; Estilo C; Mallam D; Conlin A; Patil S; Fleisher M; Cremers S; Huryn J; Hudis CA; Fornier MN
    J Oral Maxillofac Surg; 2012 Dec; 70(12):2768-75. PubMed ID: 22330331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic value of bone-turnover metabolites in the diagnosis of bone metastases in patients with lung carcinoma.
    Izumi M; Nakanishi Y; Takayama K; Kimotsuki K; Inoue K; Wataya H; Minami T; Hara N
    Cancer; 2001 Apr; 91(8):1487-93. PubMed ID: 11301396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.